Bayer Stock - Saturday deep dive on business model and outlook

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 14:54 CET. Details in the imprint.

Bayer (DE000BAY0017) combines pharmaceuticals, consumer health and agricultural technologies under one roof. This Saturday, the focus is on the group’s long-term business model and balance between growth initiatives and legal as well as financial constraints.

How Bayer is structured

Bayer’s business rests on three divisions: Pharmaceuticals, Consumer Health and Crop Science, with the latter heavily influenced by the Monsanto acquisition and the herbicide glyphosate portfolio.

In its latest annual reporting, management highlighted that pharmaceuticals and crop science generate the bulk of sales and earnings, while consumer health offers steadier, lower-volatility growth.

Long-term challenges and strategy

The group still carries a substantial debt load and legal contingencies tied to US glyphosate litigation, which constrain financial flexibility and capital allocation.

Management has outlined cost savings and portfolio measures aimed at improving cash flow and deleveraging, while continuing to invest in innovative drugs and agricultural technologies.

What the company sells

Bayer earns money with prescription medicines such as anticoagulant therapies, over-the-counter brands in pain and allergy relief, and a wide range of crop-protection products and seeds used by farmers worldwide.

Where the stock trades today

The shares of Bayer (DE000BAY0017) trade on Xetra at EUR 37.84 as of 06/19/2026, 17:35 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.